However, when the median overall survival time of CD39-high patients was compared to that of CD39-low patients in eight cancers with high CD73 expression, it was discovered that the median overall survival time of CD39-high patients was significantly shorter than that of CD39-low patients (the median overall survival 42.4 months VS 58.6 months). The gene discussed is ENTPD1; the disease is cancer.